JDJames P. Dunn

James P. Dunn

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


James P. Dunn has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Incidence and Management of Ocular Hypertension Following the 0.18 mg Fluocinolone Acetonide Implant for Non-infectious Uveitis affecting the Posterior Segment

    by Lily C Farrell, Isabella V Y Gomes, Sidra Zafar, Madison M Woods, Justin C Muste, Hemal Patel, Turner Wibbelsman, Samantha Massenzio, Julie S Kim, Sunir J Garg, et al.

    Purpose: To investigate the real-world incidence and management of ocular hypertension (OHT) following intravitreal 0.18mg fluocinolone acetonide implant (FAi, Yutiq) for non-infectious uveitis affecting the posterior segment (NIU-PS). Methods: Retrospective review of eyes treated with 0.18 mg FAi (2019–2025) with ≥1 month follow-up. Primary outcome was OHT (IOP >24 mmHg). Secondary outcomes included IOP ≥30 mmHg, >12 mmHg IOP increase from baseline, and OHT treatment. Results: A total of 275 FAi-treated eyes (178 patients, mean age: 62.87 years) were included. Patients received an average of 1.05 FAi (range:1–2), with mean follow-up of 20.59 ± 0.72 months. Mean baseline IOP was 14.30 ± 3.90 mmHg. Glaucoma and OHT were present in 28.4% and 32.4% of eyes, respectively and 38.5% were on IOP-lowering therapy. Supplemental corticosteroid injections were required in 31.3%. The OHT rate after FAi was 10.5%. Elevated IOP ≥30 mmHg occurred in 5.82%. IOP >12 mmHg from baseline occurred in 7.3%. Among OHT eyes, 41.4% resolved with observation, 44.8% required topical therapy (mean 1.78 agents), and 10.3% required incisional surgery. Higher baseline IOP (adjusted OR 1.41 per 1 mmHg increase, 95% CI:1.19–1.67) and baseline IOP-lowering medication use (OR 8.56, 95% CI:2.61–28.11) were the strongest predictors of rise in IOP. Conclusion: FAi for the treatment of NIU-PS was associated with low rates of OHT, reinforcing its safety. Eyes with higher baseline IOP and those on prior IOP-lowering medications had a substantially increased risk of OHT, highlighting the need for closer IOP monitoring in this subgroup.

  • Prolonged Undifferentiated Postoperative Pseudophakic Iridocyclitis

    by Binod Acharya, Leslie Hyman, Maurizio Tomaiuolo, Qiang Zhang, James P. Dunn


  • OUTCOMES OF PRO RE NATA VERSUS TREAT-AND-EXTEND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS FOR MYOPIC MACULAR NEOVASCULARIZATION IN MULTIETHNIC PATIENTS IN THE UNITED STATES

    by Shreya Bs Swaminathan, Raziyeh Mahmoudzadeh, Taku Wakabayashi, Mallory Bowers, Bita Momenaei, Robert M. Ba Abishek, Mirataollah Salabati, Jason Hsu, James P. Dunn

    Purpose: To compare visual outcomes and recurrence rates between pro re nata (PRN), treat-and-extend and stop (TES), and treat-and-extend with chronic maintenance dosing (TEM) regimens of anti–vascular endothelial growth factor (vascular endothelial growth factor) injections for myopic macular neovascularization (MNV) in multiethnic patients. Methods: This retrospective study included patients treated with PRN, TES, or TEM for myopic MNV using intravitreal bevacizumab or ranibizumab. The primary outcome measure was visual improvement at 12 months. Results: Overall, 127 eyes of 117 patients (75 women and 42 men) were included. The mean follow-up duration was 37.9 months. The outcomes of PRN (47 eyes [37%]), TES (52 eyes [41%]), and TEM (28 eyes [22%]) were compared. All groups showed significant visual improvement at 12 months and at the final follow-up (all P < 0.05). Visual outcomes did not differ significantly between the three groups at 12 months and the final follow-up (all P > 0.05). However, the number of eyes with recurrences was significantly higher in the PRN group and significantly lower in the TEM group during the follow-up (38%, 21%, and 11% in the PRN, TES, and TEM groups, respectively; P = 0.020). The PRN group received the fewest injections during follow-up (5.3, 10.9, and 19.9 injections in the PRN, TES, and TEM groups, respectively; P < 0.001). Conclusion: Comparing myopic MNV treatment regimens, anti-VEGF injections with PRN, TES, or TEM are effective for myopic MNV and have comparable visual outcomes. Because PRN provides favorable outcomes with fewer injections, it should be the first-line approach. However, a treat-and-extend approach with TES and TEM may be an option given individual patient factors.


  • Gonioscopy-Assisted Transluminal Trabeculotomy for the Treatment of Glaucoma in Uveitic Eyes

    by Devayu A. Parikh, Phoebe L. Mellen, Tony Kang, Wesam Shamseldin Shalaby, Marlene R. Moster, James P. Dunn

    To evaluate the outcomes of gonioscopy-assisted transluminal trabeculotomy (GATT) in adult eyes with uncontrolled uveitic glaucoma.We reviewed 16 eyes from 13 patients. Surgical success was defined...


  • HIV Retinopathy

    by James P. Dunn

  • Bilateral Hemorrhagic Optic Disc Edema in a Middle-aged Man

    by Crystal Y. Lee, Matthew R. Starr, James P. Dunn

    Identify all potential conflicts of interest that might be relevant to your comment. Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. Err on the side of full disclosure. If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response. Not all submitted comments are published. Please see our commenting policy for details.

  • A Retinal Detachment After International Travel

    by Dilru C. Amarasekera, Michael J. Ammar, James P. Dunn

    Identify all potential conflicts of interest that might be relevant to your comment. Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. Err on the side of full disclosure. If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response. Not all submitted comments are published. Please see our commenting policy for details.


  • Unilateral Retinal Arteritis and Macroaneurysm in Sarcoidosis

    by Raziyeh Mahmoudzadeh, Anand Gopal, Rebecca Soares, James P. Dunn

    Background: Sarcoidosis, an idiopathic systemic disorder characterized by noncaseating granulomas, is often associated with granulomatous uveitis. Anterior segment involvement can present with mutton-fat keratic precipitates, anterior chamber cell, and iris nodules. Sarcoid associated posterior uveitis may present with vitritis, retinal vasculitis, and choroidal lesions.Case summary: Sarcoid-associated retinal vasculitis is classically thought of as predominantly involving veins, but in this case report we describe a 76-year-old Caucasian woman presenting with bilateral posterior uveitis, unilateral optic nerve head granuloma, and retinal arteritis as the first manifestation of ocular involvement in systemic sarcoidosis.Conclusion: This case describes the uncommon first manifestation of ocular involvement in systemic sarcoidosis presenting with unilateral retinal arteritis, macroaneurysms and optic nerve head granuloma.


  • Endophthalmitis after Cataract Surgery: Changes in Management Based on Microbiologic Cultures

    by Samir N. Patel, Philip P. Storey, Hannah Levin, Maitri Pancholy, Anthony Obeid, Turner D. Wibbelsman, Brandon Kuley, Allen C. Ho, Jason Hsu, Sunir J. Garg, et al.


  • Cryptococcal Meningitis Presenting as Endophthalmitis in an Otherwise Asymptomatic Patient

    by Travis J. Peck, Michael J. Ammar, James P. Dunn

    Cryptococcus neoformans is a budding yeast that has a tropism for the central nervous system where it may cause meningitis, which has a high mortality rate. Endophthalmitis is rare and typically occurs in the setting of meningitis and disseminated disease. This report describes an atypical presentation of cryptococcal endophthalmitis and outlines the appropriate workup and management for this disease. A case report is presented. A 66-year-old man on chemotherapy who presented with blurry vision without any extraocular symptoms was diagnosed with cryptococcal endophthalmitis and found to have underlying bloodstream and central nervous system infection on subsequent workup. He was treated with intravenous and intravitreal antifungals and remained systemically well, although a large subretinal mass lesion remained stable at 2-month follow-up. Cryptococcal endophthalmitis may be the initial presentation of disseminated cryptococcal disease. If vitreous cultures grow Cryptococcus, clinicians should presume that meningitis is present, regardless of symptoms, until proven otherwise.